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Objectives: The use and combined use of
psychotropic drugs and alcohol among older adults is a
growing public health concern and should be constantly
monitored. Relevant studies are scarce in Germany.
Using data of the most recent national health survey, we
analyse prevalence and correlates of psychotropic drug
and alcohol use among this population.
Methods: Study participants were people aged 60–
79 years (N=2508) of the German Health Interview and
Examination Survey for Adults 2008–2011. Medicines
used during the last 7 days were documented.
Psychotropic drugs were defined as medicines acting
on the nervous system (ATC code N00) excluding
anaesthetics (N01), analgesics/antipyretics (N02B), but
including opiate codeines used as antitussives (R05D).
Alcohol consumption in the preceding 12 months was
measured by frequency (drinking any alcohol-
containing beverages at least once a week/a day) and
quantity (alcohol consumed in grams/day; cut-offs: 10/
20 g/day for women/men defining moderate and risky
drinking). SPSS complex sample module was used for
analysis.
Results: 21.4% of study participants use psychotropic
medications, 66.9% consume alcohol moderately and
17.0% riskily, 51.0% drink alcohol at least once a week
and 18.4% daily, 2.8% use psychotropic drugs
combined with daily alcohol drinking. Among
psychotropic drug users, 62.7% consume alcohol
moderately, 14.2% riskily. The most frequently used
psychotropic medications are antidepressants (7.9%)
and antidementia (4.2%). Factors associated with a
higher rate of psychotropic drug use are female sex,
worse health status, certified disability and
polypharmacy. Risky alcohol consumption is positively
associated with male sex, smoking, upper social class,
better health status, having no disability and not living
alone.
Conclusions: Despite the high risk of synergetic
effects of psychotropic drugs and alcohol, a substantial
part of older psychotropic drug users consume alcohol
riskily and daily. Health professionals should talk about
the additional health risks of alcohol consumption when
prescribing psychotropic drugs to older adults.
INTRODUCTION
Psychotropic drugs such as antidepressants,
sedatives or hypnotics are characterised by
their impact on the central nervous system
(CNS) and influence perception, mood, con-
sciousness or behaviour. They are established
clinical treatments for a variety of neuro-
logical and mental diseases but also harbour
risks of side effects and the development of
dependency. Older adults, due to the loss of
close persons, social networks or autonomy,
may suffer from emotional and mental disor-
ders and are a major group of psychotropic
drug users.1 2 Nevertheless, the use of psy-
chotropic medications by older adults should
be considered carefully. Older adults are
particularly vulnerable to drug-related
adverse health consequences due to
significant changes in pharmacokinetic and
Strengths and limitations of this study
▪ A large sample of concurrent data on medication
use, sociodemographic and health characteristics
allows analyses of psychotropic drug and
alcohol use on a population representative level.
▪ The short observation period (7 days) minimises
recall bias concerning medication use, and
quality control is ensured by checking original
packages.
▪ Alcohol consumption was measured by fre-
quency and quantity.
▪ The use of psychotropic drugs is likely to be
underestimated as people who are institutiona-
lised and those with severe disease and psychi-
atric disorders (including cognitive impairments,
depression, dementia, etc) are less likely to par-
ticipate in national health surveys.
▪ Under-reporting of alcohol use is possible as
people tend to answer questions concerning
intoxicating substances according to social
desirability.
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pharmacodynamic properties of drugs related to ageing
processes.3 Additionally, an age-related increase in multi-
morbidity and polypharmacy among older adults aggra-
vates those risks.4
Alcohol is a substance with psychotropic characteristics
and also widely consumed by older adults. Sharing the
same metabolic enzymes with psychotropic drugs,
alcohol is broken down mainly in the liver.5 The intake
of alcohol alters the activity of the metabolic enzymes
and may result in pharmacokinetic and pharmacody-
namic interactions with psychotropic drugs.5 Combined
use of psychotropic drugs with alcohol, even in small
amounts, can produce synergistic effects and therefore
may be harmful and risky for older adults.5 6 For
example, alcohol enhances the sedative effects of fre-
quently used antidepressants, benzodiazepines and sleep
medications,5 increasing greatly the risks of falls and hip
fractures.7 The use of alcohol and psychotropic drugs
among older adults, particularly combined use of both,
constitutes a growing public health concern and should
be constantly monitored and carefully reviewed over
time.8
Psychotropic drug use and alcohol consumption have
been investigated previously in the general adult popula-
tion or in studies regarding alcohol-interactive medica-
tion use.9–12 Only a few studies investigated specifically
the use of psychotropic drugs and alcohol among older
adults.12–14 Our own previous study, which also investi-
gated the use of psychotropic drugs and alcohol among
older adults, was conducted using data of a national
health survey from 1998.14 An update is needed, given
significant changes in demographics, health behaviour
as well as disease profiles over the last decade.
With the recent data of the German Health Interview
and Examination Survey for Adults 2008–2011, we
analyse prevalence and correlates of psychotropic medi-
cine use and alcohol consumption as well as the con-
comitant use of both among older people.
METHODS
Study design and participants
As database for the present study served the German
Health Interview and Examination Survey for Adults,
wave 1 (DEGS1), which was conducted by the Robert
Koch Institute from November 2008 to December 2011.
DEGS1 aims to provide representative data on the
health of adults aged 18–79 years living in Germany.
Details of the study design, sampling strategy and proto-
col have been published elsewhere.15 16 Briefly, a two-
stage, probability-cluster sampling procedure was
applied. A sample of 180 primary sample units, repre-
sentative of municipality sizes and structures in
Germany, were selected. In the second stage, random
samples were drawn from local population registries
stratified by age and sex. The final sample aged 18–
79 years with completed interview and examination data
amounted to 7115 adults.15 16
For the present analyses, only participants aged 60–
79 years with complete interview and examination data
were included, resulting in a total of 2508 participants
(1277 women, 1231 men) (table 1).
DEGS1 was approved by the Federal and State
Commissioners for Data Protection and the
Charité-Universitätsmedizin Berlin ethics committee
(number EA2/047/08). Survey participants provided
written informed consent prior to interviews and
examinations.
Data collection
Data collection in DEGS1 was conducted via self-
administered questionnaires, standardised physician-
administered computer-assisted personal interviews
(CAPI), standardised personal interviews on medicine
usage, medical examinations, physiological measure-
ments and laboratory tests.15
Self-administered questionnaires were used to collect
data on sociodemographic characteristics (age, sex,
region of residence), individual information on house-
hold size (number of persons living in household),
income, profession and educational attainment,
health-related behaviour (such as tobacco use), dietary
and nutritional habits (including alcohol consumption),
self-rated health status and officially certified disability.15
Detailed information on medication use was recorded
by trained health professionals. In the invitation letter,
participants were asked to bring the original packages of
all medications—prescribed and Over-The-Counter
(OTC) products—used during the past 7 days to the
examination site for the purpose of documentation and
verification. This permitted automated recording of
unique product identifiers and drug coding according
to the WHO ‘Anatomical Therapeutic Chemical’ (ATC)
classification system.17
Defining psychotropic drug use and measuring alcohol
consumption
In the present study, we included psychotropic drugs
belonging to the nervous system class (ATC code N00)
as well as opiates used as antitussives (ATC code R05DA)
and aspirin–caffeine combination preparations (ATC
code N02BA71) considering their CNS effects.14 We
excluded other analgesics and antipyretics such as
aspirin and paracetamol (ATC code N02B), local anaes-
thetics (ATC code N01B), homeopathic drugs of the
ATC class N00 and drugs with indistinct active ingredi-
ents.14 Psychotropic drugs with herbal active ingredients
were considered and coded separately under specific
subgroups.
Alcohol consumption during the preceding 12 months
was recorded via a standardised food-frequency question-
naire. We asked each survey participant ‘How often have
you taken these alcohol-containing beverages over the last 12
months?’ differentiating according to the type of alcoholic
beverages (namely ‘beer’, ‘wine, champagne, fruit wine’,
‘cocktail and other alcohol-containing mixtures’ and
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Table 1 Study population, prevalence of psychotropic drug use and alcohol consumption among adults aged 60– 79 years by sociodemographic and health-related factors:




use (n=518) Alcohol consumption—by frequency Alcohol consumption—by quantity
At least once a week
(n=1295)






N Per cent Per cent 95% CI Per cent 95% CI Per cent 95% CI Per cent 95% CI Per cent 95% CI
Total 2508 100.0 21.4 19.3 to 23.7 51.0 48.1 to 53.9 18.4 16.3 to 20.7 66.9 64.1 to 69.5 17.0 14.9 to 19.2
Sex
Men 1231 46.9 15.9 13.2 to 18.9 68.4** 64.8 to 71.8 29.7** 26.2 to 33.4 67.3 63.7 to 70.7 23.9** 20.7 to 27.3
Women 1277 53.1 26.3** 23.2 to 29.7 35.2 31.8 to 38.9 8.1 6.4 to 10.2 66.5 62.6 to 70.2 10.9 9.0 to 13.2
Age group, years
60–69 1398 52.5 18.1 15.5 to 21.1 52.9 49.1 to 56.7 18.9 16.1 to 22.0 64.4 61.0 to 67.7 18.8 16.0 to 22.0
70–79 1110 47.5 25.1* 21.4 to 29.1 48.8 44.9 to 52.7 17.8 15.1 to 21.0 69.7* 65.5 to 73.6 14.8 12.1 to 18.0
Region of residence§
Northern Germany 644 25.8 19.4 15.4 to 24.1 42.4 36.6 to 48.3 14.5 11.0 to 18.8 66.2 60.7 to 71.3 16.8 12.6 to 22.0
Central Germany 1141 41.3 22.0 19.0 to 25.3 49.1 45.2 to 53.0 16.4 13.6 to 19.7 69.1 65.5 to 72.5 12.8 10.8 to 15.2
Southern Germany 723 32.9 22.3 18.4 to 26.8 60.2** 55.7 to 64.6 24.0* 20.0 to 28.4 64.7 59.1 to 69.9 22.3** 18.3 to 26.9
Social status
Lower 436 24.1 25.4* 20.6 to 30.9 39.4 33.3 to 45.8 16.2 12.1 to 21.4 65.2 58.4 to 71.4 12.8 9.2 to 17.4
Middle 1489 59.3 21.4 18.6 to 24.4 51.3 47.5 to 55.0 17.9 15.3 to 20.7 67.8 64.5 to 70.8 16.0 13.6 to 18.7
Upper 562 16.5 15.3 12.0 to 19.4 65.7** 59.8 to 71.1 23.3 19.2 to 27.9 67.2 61.8 to 72.2 26.3** 21.6 to 31.7
Living alone
Yes 507 21.3 27.7* 22.7 to 33.4 36.0 29.8 to 42.7 9.9 7.2 to 13.5 62.5 56.3 to 68.3 12.0 8.9 to 16.0
No 1987 78.7 19.6 17.4 to 22.2 55.0** 51.9 to 58.1 20.6** 18.1 to 23.4 68.3 65.4 to 71.1 18.2** 16.0 to 20.7
Smoking
Smoker 302 12.5 17.7 12.7 to 24.0 53.0 45.1 to 60.7 30.4** 23.7 to 38.0 55.5** 48.4 to 62.5 26.2** 19.9 to 33.7
Ex-smoker 927 36.3 21.0 17.6 to 24.9 60.7** 56.0 to 65.1 21.7 18.3 to 25.7 66.1 61.7 to 70.2 21.4 17.9 to 25.4
Never-smoker 1265 51.2 22.1 19.0 to 25.6 44.2 40.4 to 48.1 13.3 11.0 to 16.0 70.6 66.5 to 74.4 11.7 9.7 to 14.1
Health status
Better 1503 58.2 13.1 11.0 to 15.5 55.7** 52.0 to 59.4 20.9* 18.1 to 24.0 67.1 63.4 to 70.6 19.8** 16.9 to 23.1
Worse 986 41.8 32.5** 28.7 to 36.6 44.3 40.2 to 48.5 14.8 12.2 to 17.8 66.6 62.7 to 70.3 13.0 10.9 to 15.5
Certified disability
Yes 649 29.1 30.6** 26.0 to 35.5 47.8 42.1 to 53.6 14.8 11.6 to 18.7 66.9 62.2 to 71.3 13.5 10.4 to 17.4
No 1801 70.9 17.2 15.1 to 19.6 52.4 49.2 to 55.6 19.8* 17.4 to 22.4 66.9 63.8 to 69.8 18.4 16.2 to 20.9
Polypharmacy¶
Yes 771 30.7 37.8** 33.8 to 42.1 46.5 42.4 to 50.7 17.6 14.8 to 20.8 67.7 63.7 to 71.4 14.5 12.2 to 17.3
No 1730 69.3 9.4 7.5 to 11.8 54.3** 50.7 to 57.9 19.1 16.2 to 22.3 66.5 63.0 to 69.9 18.7* 16.0 to 21.8
Missing values for: psychotropic drug use (n=7), alcohol use at least once a week and once a day (n=135), moderate and risky drinking (n=46), social status (n=16), living alone (n=14), smoking
(n=14), health status (n=19), certified disability (n=58), polypharmacy (n=7).
*p<0.05 or **p<0.01, Rao-Scott second-order χ2 test; figures in bold denote statistical significance.
†Moderate drinking: average daily consumption of alcohol between >0 and<10 g for women, and between >0 and<20 g for men.
‡Risky drinking: average daily consumption of alcohol≥10 g for women, and≥20 g for men.
§Regions: Northern Germany (federal states: Berlin, Brandenburg, Bremen, Hamburg, Lower Saxony, Mecklenburg-Vorpommern, Schleswig-Holstein); Central Germany (Hesse, North
Rhine-Westphalia, Saxony, Saxony-Anhalt, Thuringia), Southern Germany (Baden-Württemberg, Bavaria, Rhineland-Palatinate, Saarland).
¶Polypharmacy: use of five or more drugs including prescribed and OTC drugs in the last 7 days.


















‘spirits’). Eleven possible answer choices were provided
ranging from ‘never’ to ‘more than five times daily’.
Based on frequency of alcohol consumption, participants
were classified as ‘at least once a week’ (‘one to two times
a week’, ‘three to four times a week’, ‘five to six times a
week’, ‘once daily’, to ‘more than five times daily’)—or
‘daily’ (‘once daily’, ‘two times daily’, ‘three times daily’,
‘four to five times daily’, ‘more than five times daily’)
alcohol users.
For each consumed alcohol-containing beverage, the
estimated volume (for beverages with high percentage
of alcohol, this would be gauged to the nearest 2 cL)
was recorded. The mean amount of alcohol consumed
every day (grams per day) was computed for each survey
participant by multiplying the frequency and amount of
alcohol in grams contained in the consumed drinks
according to methods previously described.18
Internationally, limits for risky alcohol consumption vary
widely and do not differentiate according to age.19 In
Germany, the threshold for risky drinking is set at ≥10–
12 g/day of alcohol for women and ≥20–24 g/day for
men.20 21 Considering our study participants were
60 years and older—and in the absence of age-specific
limits—we adopted the lower limits of ≥10 g/day for
women and ≥20 g/day for men to classify risky drink-
ing.14 Moderate drinking was then defined as consump-
tion of alcohol between >0 and <10 g/day for women,
and between >0 and <20 g/day for men.
Covariables
Sociodemographic variables included sex, age and
region of residence, social status and household size. Age
groups included were 60–69 and 70–79 years. Regarding
the region of residence, we considered the possible geo-
graphical differences in alcohol consumption among
people in Germany and grouped the regions into three
areas with each including several federal states: Northern
Germany (Berlin, Brandenburg, Bremen, Hamburg,
Lower Saxony, Mecklenburg-Vorpommern and
Schleswig-Holstein); Central Germany (Hesse, North
Rhine-Westphalia, Saxony, Saxony-Anhalt and Thuringia)
and Southern Germany (Baden-Württemberg, Bavaria,
Rhineland-Palatinate and Saarland). Socioeconomic
status (SES) was classified as lower, middle and upper
using an established index, including information on
education, professional status and household income.22
Household size was categorised as living alone if only one
single person was reported in a household.
Health-related variables included smoking status, self-
perceived health status, having a certified disability and
polypharmacy. Smoking status was assessed using four
categories, namely ‘yes, daily’, ‘yes, occasionally’,
‘ex-smoker’ and ‘never smoker’. For the present ana-
lyses, we classified smokers as those who answered ‘yes,
occasionally’ and ‘yes, daily’, while the other two
categories remained unchanged. Information on
self-perceived health status was also collected via self-
administered questionnaires. The possible five answer
choices were dichotomised as ‘better’ (very good or
good) and ‘worse’ (fair, bad or very bad). Additionally,
people were asked, if they had an officially certified dis-
ability (yes/no). Polypharmacy was assumed if five or
more medicines (prescription and/or OTC) were used
in the past 7 days. Additionally, for the purpose of con-
ducting sensitivity analyses, we defined polypharmacy by
(1) counting the number of prescription drugs only and
(2) excluding psychotropic drugs.
Statistical analyses
All statistical analyses were performed using SPSS statis-
tical software (V.20.0, SPSS, Chicago, Illinois, USA). In
order to adjust for sample clustering effects, the SPSS
complex samples module was used for all analyses.
Sampling weights were used to correct deviations in the
sample from the structure of the German general popu-
lation of 31 December 2010 with respect to age, sex,
region of residence, type of municipality, nationality and
educational level.16
Descriptive statistics were used to examine character-
istics of the study population. Weighted prevalence rates
of psychotropic drug use, alcohol consumption and
combined use of both substances were estimated and
stratified according to above described covariables.
Differences in the prevalence estimates between sub-
groups were tested by second-order Rao-Scott χ2 tests.
ORs and 95% CIs were derived from multivariable logis-
tic regression models with psychotropic drug use,
alcohol consumption and combined use of both sub-
stances as dependent variables and all covariables as pre-
dictive variables. We also looked at the association of
body mass index (BMI) and sports activities with psycho-
tropic drug use and alcohol consumption. We repeated
the regression analyses adding BMI (<25, 25–30,
≥30 kg/m2) and sports activities (no sports,<2 hours/
week and ≥2 hours/week in the past 3 months) in
models. Both were not significantly associated with psy-
chotropic drug use—overall and in major subgroups—
and alcohol consumption (data not shown). For each
variable, weighted proportion and unweighted n depict
the number of participants with complete information.
The number of persons with missing values was explicitly
stated for each variable with a range of 0.3% (n=7) for
psychotropic drug use, 1.8% (n=48) for risky alcohol
drinking, to 5.4% (n=135) for daily alcohol drinking.
Persons with missing values were excluded from the ana-
lyses, with pairwise deletion for descriptive and listwise
deletion for multivariable analyses. A probability level
for statistically significant group differences was consid-
ered at p<0.05 based on two-sided tests.
RESULTS
Our study includes 2508 people aged 60–79 years, with
an almost equal proportion of women and men. Half of
our study participants are never-smokers, one-quarter
resides in Northern Germany and every fourth has a
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lower SES. Nearly 60% of the participants perceive their
health status as ‘better’, about 30% report having a certi-
fied disability or being exposed to polypharmacy and
about 20% of older adults live alone (table 1).
Overall, 21.4% of all study participants use at least one
psychotropic medication, 66.9% consume alcohol mod-
erately and 17.0% riskily. About 51.0% of older adults
drink alcohol at least once a week, while 18.4% are daily
alcohol consumers (table 1).
Stratified by sociodemographic and health-related cov-
ariables, a significantly higher prevalence rate of psycho-
tropic drug use is found among women, the older age
group (70–79 years), people with a lower social status,
those living alone, people with a worse health status,
those having a certified disability and participants with
polypharmacy. In contrast, a significantly higher preva-
lence rate of weekly alcohol use is found among men,
people residing in Southern Germany, those with an
upper social status, people living with others, those with
a good health status, smokers and people without poly-
pharmacy. Similar results are found for daily and risky
alcohol use (table 1). Concerning moderate drinking,
higher prevalence rates are found among the older age
group (70–79 years), but lower rates are found among
current smokers (table 1).
Table 2 depicts the use of psychotropic drugs
according to specific subgroups. In total, 518 older
participants consume 740 psychotropic drugs. Of these
Table 2 Use of psychotropic drugs according to specific subgroups among adults aged 60 and 79 years: German Health
Interview and Examination Survey for Adults (DEGS1) 2008–2011
ATC code
Medication class/active
pharmaceutical ingredient No. of drugs No. of users
User prevalence
Per cent 95% CI
Synthetics 571 404 16.9 14.9 to 19.1
N02A Narcotic analgesics 104 96 4.1 3.2 to 5.3
N02AX51 Tilidin 31 30 1.3 0.8 to 2.0
N02AX02 Tramadol 26 26 0.9 0.6 to 1.5
N02C Antimigraine preparations 7 7 0.4 0.2 to 1.0
N03 Antiepileptics 70 63 2.3 1.7 to 3.3
N03AF01 Carbamazepin 19 17 0.7 0.3 to 1.5
N03AX12 Gabapentin 17 17 0.6 0.3 to 1.2
N03AX16 Pregabalin 15 13 0.4 0.2 to 0.8
N04 Antiparkinsonian agents 47 32 1.2 0.7 to 2.0
N04BA11 Levodopa and benserazide 18 16 0.7 0.3 to 1.4
N05A Antipsychotics 24 21 0.8 0. 5 to 1.2
N05B Anxiolytics 48 48 2.2 1.5 to 3.1
N05BA Benzodiazepine derivatives 46 46 2.1 1.4 to 3.1
N05BA08 Bromazepam 15 15 0.9 0.5 to 1.8
N05C Hypnotics and sedatives 52 42 1.3 0.9 to 1.9
N05CD Benzodiazepines 11 11 0.4 0.2 to 0.9
N05CF Benzodiazepine-related drugs 28 28 0.8 0.5 to 1.3
N06A Antidepressants 169 151 6.7 5.5 to 8.5
N06AA Non-selective monoamine reuptake inhibitors 82 80 3.8 2.8 to 5.3
N06AA09 Amitriptylin 26 25 1.4 0.8 to 2.3
N06AA05 Opipramol 21 21 1.1 0.5 to 2.2
N06AB Selective serotonin reuptake inhibitors (SSRIs) 47 47 2.0 1.4 to 2.7
N06AB04 Citalopram 29 29 1.0 0.7 to 1.6
N06B Psychostimulants 5 5 0.5 0.1 to 1.8
N06D Antidementia drugs 10 10 0.4 0.2 to 1.0
N07 Others 35 34 1.5 1.0 to 2.5
Phytomedicines 169 158 6.5 5.4 to 7.8
N06DP01 Ginkgo biloba 89 88 3.8 3.0 to 4.8
N06AP01 St John’s wort 27 27 1.1 0.8 to 1.7
N05CP01/06 Valerian 44 42 1.5 1.0 to 2.1
N05CP04/05/08 Others used for sleep 9 9 0.4 0.1 to 1.0
Specific drug classes of interest
Antidepressants (N06A synthetics and St John’s wort) 196 173 7.9 6.5 to 9.5
Antidementia drugs (N06D synthetics and Ginkgo biloba) 99 97 4.2 3.3 to 5.4
Hypnotics and sedatives (N05C synthetics, valerian and others
used for sleep)
105 98 3.3 2.6 to 4.3
Benzodiazepines (N05BA, N05CD, N03AE01, N05CF) 86 84 3.3 2.5 to 4.4
All psychotropic drugs (synthetics and phytomedicines) 740 518 21.4 19.3 to 23.7
All percentages and 95% CIs were weighted according to the German national population on 31 December 2010.
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drugs, 571 (77.2%) are synthetics, while 169 (22.8%)
are phytomedicines. The user prevalence for synthetics
and phytomedicines amounts to 16.9% and 6.5%,
respectively.
Among synthetic drugs, antidepressants are most fre-
quently used (6.7%), followed by narcotic analgesics
(4.1%), antiepileptics (2.3%) and anxiolytics (2.2%)
(table 2). In contrast, synthetic antimigraine prepara-
tions, antidementia drugs, psycho-stimulants and antipsy-
chotics are used by <1% of the study population. The
so-called Z-drugs under the ATC code N05CF
(benzodiazepine-related drugs) account for the majority
of hypnotics and sedatives (N05C) with a user preva-
lence rate of 0.8% (zopidem 0.5% and zopiclone 0.3%,
data not shown in table 2). Almost half of synthetic anti-
depressants are non-selective monoamine reuptake inhi-
bitors, while selective serotonin reuptake inhibitors
account for 27.8%. Nearly, all anxiolytics originate from
the medication group of benzodiazepine derivatives.
About 3.3% of older adults use benzodiazepine or
benzodiazepine-related drugs (table 2).
The most frequently used phytomedicines are Ginkgo
biloba (3.8%), followed by valerian (1.5%) and St John’s
wort (1.1%). Looking at the total of phytomedicine and
synthetics use, antidepressants (7.9%) and antidementia
drugs (4.2%) are the most frequently used psychotropic
medications among older adults (table 2).
Table 3 describes the use of specific psychotropic drug
groups of interest differentiated according to sociode-
mographic and health-related factors. A high use of syn-
thetic medication, but not phytomedicines, is found
among persons with a low social status and among those
with a certified disability. People with a worse health
status and those exposed to polypharmacy are signifi-
cantly more likely to use any psychotropic drugs.
Similarly, there is a greater probability of psychotropic
medicine use among people with a certified disability
(with exception of phytomedicines, hypnotics and seda-
tives and antidementia drugs).
Women are more likely to use all subgroups of psycho-
tropic drugs with the exception of antiepileptics. People
who live alone significantly more often use antidepres-
sants and antidementia drugs, while people with a lower
social status are more likely to use narcotic analgesics.
The region of residence and smoking status are less
likely to be associated with the use of subgroups of psy-
chotropic drugs except that ex-smokers are significantly
more likely to use antiepileptics (table 3).
Figure 1 depicts psychotropic drug use in relation to
daily and risky alcohol drinking. Approximately
two-thirds (75.5%) of those who drink daily also drink
riskily with a prevalence rate of 13.9% (areas A6 and
A5). Among those who drink daily, only one-fifth
(20.9%) do not drink riskily and do not use psycho-
tropic drugs (area A3). The prevalence of psychotropic
drug use combined with daily alcohol drinking amounts
to 2.8% (areas A5 and A2), the majority of this group
drinks also riskily (area A5, prevalence 2.1%).
The proportions of alcohol users according to fre-
quency and volume of alcohol use and stratified by spe-
cific psychotropic drug groups are shown in table 4. The
majority of all psychotropic drug users (62.7%) drink
alcohol moderately, while 14.2% drink riskily. Nearly
half of psychotropic drug users (45.7%) drink alcohol at
least once a week, while 12.9% drink alcohol daily.
There are no significant differences within the sub-
groups of alcohol consumption in relation to the sub-
groups of psychotropic drugs (table 4).
Table 5 presents factors associated with psychotropic
drug, alcohol and the combined use of both substances.
Polypharmacy and female sex are correlates of psycho-
tropic drug use, overall and for major subgroups of
interest. Correlates of daily drinking combined with psy-
chotropic drug use are worse health status and polyphar-
macy. In contrast, male sex and residing in Southern
Germany are predictors for alcohol use. Lower social
status, worse health status, disability and living alone are
adversely associated with any alcohol drinking or risky
drinking, whereas positively associated with any psycho-
tropic drug use or specific subgroups (antidepressants
and narcotic analgesics). Older age (70–79 years) is asso-
ciated with the use of phytomedicine only, while
ex-smokers are more likely to use phytomedicines, hyp-
notics and sedatives and to practice risky alcohol con-
sumption (table 5). Sensitivity analyses involving
polypharmacy defined by including prescription drugs
only show no substantial changes. Sensitivity analyses
involving polypharmacy without psychotropic medicines
show that the associations between polypharmacy and
any psychotropic drug use are attenuated while the stat-
istical significance remains unchanged (OR 1.88, 95%
CIs 1.42 to 2.48, p<0.0001). Also, the associations of
polypharmacy with daily or risky alcohol drinking
remain non-significant (data not shown).
DISCUSSION
The present study provides representative data on psy-
chotropic drug use and alcohol consumption among
adults aged 60–79 years in Germany. About 21.4% of
older adults use at least one psychotropic medication in
the past 7 days, more than half consume any
alcohol-containing beverage, about 17–18% practice
daily and/or risky alcohol drinking, and 2.8% use psy-
chotropic drugs combined with daily alcohol drinking.
More than half of those who use any psychotropic drugs
consume alcohol moderately or at least once a week,
while about 13–14% consumes alcohol daily or riskily.
Factors associated with a higher rate of psychotropic
drug use are female sex, worse health status, certified
disability and polypharmacy. Correlates of higher rates
of alcohol consumption are male sex, living in Southern
Germany, upper social class, having a good health status
and not living alone.
Using the same methods, our previous study based on
data from 1998 finds prevalence rates of psychotropic
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Table 3 Prevalence of specific psychotropic drugs’ use among adults aged 60–79 years by sociodemographic and health-related factors: German Health Interview and Examination Survey for Adults (DEGS1)
2008–2011









Per cent 95% CI Per cent 95% CI Per cent 95% CI Per cent 95% CI Per cent 95% CI Per cent 95% CI Per cent 95% CI Per cent 95% CI
Sex
Men 13.1 10.8 to 16.0 3.7 2.6 to 5.1 3.4 2.4 to 4.8 1.6 .9 to 2.6 3.3 2.0 to 5.3 1.7 1.0 to 2.8 3.1 2.0 to 4.7 3.2* 2.1 to 5.0
Women 20.2** 17.3 to 23.5 9.0** 7.2 to 11.2 11.8** 9.4 to 14.7 4.9** 3.7 to 6.6 4.9 3.6 to 6.5 4.7** 3.3 to 6.5 5.2 3.8 to 7.0 1.5 0.9 to 2.6
Age group, years
60–69 14.7 12.3 to 17.6 4.3 3.3 to 5.6 7.3 5.5 to 9.7 2.8 2.0 to 3.9 4.2 2.8 to 6.2 2.3 1.6 to 3.3 2.1 1.4 to 3.2 2.7 1.8 to 3.9
70–79 19.3* 15.9 to 23.1 8.9** 7.0 to 11.4 8.5 6.3 to 11.3 4.0 2.8 to 5.7 4.1 3.0 to 5.7 4.4* 2.9 to 6.6 6.5** 4.7 to 8.8 2.0 1.1 to 3.6
Region of residence‡‡
Northern Germany 15.6 12.3 to 19.6 5.2 3.5 to 7.8 6.6 4.6 to 9.4 2.6 1.5 to 4.5 4.0 2.4 to 6.4 2.3 1.3 to 3.9 3.0 1.8 to 5.0 2.6 1.4 to 4.6
Central Germany 16.1 13.3 to 19.4 7.7 5.9 to 10.0 7.5 5.5 to 10.0 3.7 2.6 to 5.4 4.0 2.8 to 5.6 3.7 2.5 to 5.3 5.2 3.7 to 7.4 1.9 1.2 to 3.2
Southern Germany 18.9 15.0 to 23.5 6.0 4.3 to 8.2 9.4 6.7 to 12.9 3.4 2.2 to 5.3 4.5 2.7 to 7.4 3.6 2.0 to 6.4 3.8 2.4 to 5.9 2.6 1.4 to 4.9
Social status
Lower 21.9* 17.2 to 27.4 4.4 2.7 to 7.1 8.4 5.6 to 12.4 3.0 1.7 to 5.5 7.3** 4.9 to 10.7 4.0 2.2 to 7.2 3.1 1.6 to 5.9 1.8 0.8 to 4.2
Middle 16.6 14.1 to 19.5 7.2 5.7 to 9.1 8.2 6.3 to 10.8 3.5 2.5 to 4.8 3.5 2.4 to 5.0 3.1 2.1 to 4.6 4.6 3.3 to 6.3 2.7 1.7 to 4.1
Upper 10.4 7.8 to 13.9 6.8 4.6 to 9.9 5.5 3.7 to 8.1 3.4 2.0 to 5.9 1.9 1.1 to 3.5 3.0 1.6 to 5.5 4.0 2.5 to 6.4 1.6 0.7 to 3.8
Living alone
Yes 22.4* 18.0 to 27.6 9.3* 6.2 to 13.6 14.2** 10.4 to 19.1 3.4 1.9 to 5.8 5.2 3.3 to 8.2 5.0 2.8 to 8.9 7.0* 4.3 to 11.3 2.3 1.1 to 4.6
No 15.4 13.2 to 17.9 5.7 4.5 to 7.1 6.1 4.7 to 7.9 3.3 2.5 to 4.4 3.9 2.8 to 5.3 2.8 2.0 to 3.9 3.4 2.5 to 4.5 2.3 1.6 to 3.4
Smoking
Smoker 14.1 9.9 to 19.7 3.9 1.9 to 7.7 7.0 4.4 to 10.9 2.8 1.3 to 5.9 4.7 2.5 to 8.8 2.4 1.1 to 5.0 1.3 .5 to 3.5 2.5 1.1 to 6.0
Ex-smoker 16.1 13.0 to 19.6 6.9 5.1 to 9.4 5.8 4.1 to 8.2 3.8 2.5 to 5.7 5.3 3.4 to 8.3 2.7 1.6 to 4.7 4.2 2.8 to 6.2 3.5* 2.2 to 5.7
Never-smoker 17.7 14.7 to 21.3 6.3 4.9 to 7.9 9.0 6.8 to 11.8 3.2 2.2 to 4.5 3.2 2.2 to 4.5 4.0 2.7 to 5.7 4.3 3.1 to 6.0 1.4 0.8 to 2.4
Health status
Better 9.2 7.4 to 11.4 5.2 3.9 to 6.9 4.9 3.7 to 6.6 2.3 1.6 to 3.3 1.2 0.5 to 2.6 1.9 1.2 to 3.1 3.1 2.2 to 4.3 1.1 0.6 to 2.0
Worse 27.3** 23.7 to 31.3 8.2* 6.3 to 10.5 12.0** 9.3 to 15.3 4.8* 3.4 to 6.8 8.1** 6.2 to 10.6 5.2** 3.6 to 7.5 5.4* 3.8 to 7.7 3.9** 2.6 to 5.9
Certified disability
Yes 27.3** 23.1 to 32.1 6.1 4.1 to 9.2 11.6* 8.5 to 15.5 3.7 2.4 to 5.6 7.7** 5.4 to 10.8 5.0* 3.2 to 7.7 4.7 2.8 to 8.0 5.0** 3.1 to 7.9
No 12.1 10.1 to 14.4 6.6 5.3 to 8.2 6.3 4.9 to 8.0 3.0 2.2 to 4.0 2.5 1.7 to 3.7 2.5 1.7 to 3.6 4.1 3.1 to 5.4 1.3 0.8 to 2.0
Polypharmacy§§
Yes 31.2** 27.3 to 35.4 10.9** 8.8 to 13.4 15.0** 12.0 to 18.6 6.1** 4.6 to 8.1 8.4** 6.4 to 10.9 6.3** 4.5 to 8.7 7.4** 5.5 to 9.9 4.6** 3.1 to 6.7
No 6.4 4.8 to 8.6 3.3 2.2 to 4.9 2.6 1.7 to 4.0 1.3 0.8 to 2.2 1.0 0.4 to 2.5 1.1 0.5 to 2.3 1.8 1.1 to 3.0 0.7 0.4 to 1.1
*p<0.05 or **p<0.01, comparison within specific subgroup, the Rao-Scott second-order χ2 test. Figures in bold denote statistical significance.
Missing values for: social status (n=16), living alone (n=14), smoking (n=14), health status (n=19), certified disability (n=58), polypharmacy (n=7).
All percentages and 95% CIs were weighted according to the German national population of 31 December 2010.
†N06A synthetics and St John’s wort (N06AP01).
‡N05C synthetics, valerian and others used for sleep (N05CP).
§N02A.
¶N05BA, N05CD, N03AE01 and N05CF.
**N06D synthetics and Ginkgo biloba (N06DP01).
††N03.
‡‡Regions: Northern Germany (federal states: Berlin, Brandenburg, Bremen, Hamburg, Lower Saxony, Mecklenburg-Vorpommern, Schleswig-Holstein); Central Germany (Hesse, North
Rhine-Westphalia, Saxony, Saxony-Anhalt, Thuringia), Southern Germany (Baden-Württemberg, Bavaria, Rhineland-Palatinate, Saarland).


















drug use of 20.1%, alcohol use of 47.3% and risky drink-
ing of 15.1%,14 which are comparable to findings of the
present study. Yet, comparability of our results with other
national and international studies is limited as there are
great differences in study design, data collection, obser-
vational windows and definitions of psychotropic drugs
and risky alcohol consumption.
A regional population-based study of health in the
Pomeranian area of Germany reports that among adults
aged 60–79 years, 3.8% of men and 6.8% of women use
sedatives, hypnotics or anxiolytics during the 7 days pre-
ceding the data collection.23 In our study, 3.3% (1.6%
hypnotics and sedatives+1.7% benzodiazepines) of the
men and 9.6% (4.9% hypnotics and sedatives+4.7% ben-
zodiazepines) of the women use sedatives, hypnotics and
benzodiazepines and related drugs. The Pomeranian
study includes more drugs of the substance groups seda-
tives, hypnotics or anxiolytics than our study.23 In our
analyses, no use of barbiturates was included, while anti-
epileptic drugs and anxiolytics were analysed separately.
The use of opioids with a prevalence rate of 0.9% in
men and 1.6% in women in the Pomeranian study23 is
lower than our findings of 3.3% in men and 4.9% in
women. Higher values in our study could be based on
differences in definition of opioids. Our study includes
not only opioids used as analgesics but also as
antitussives.
International population-based health surveys observe
similar prevalence rates for the use of subgroups of psy-
chotropic drugs as our study. The US National Health
and Nutrition Examination Survey (NHANES) 2007–
2012 finds a prevalence of opioid analgesics’ use in the
past 30 days of 7.9% (men 6.9%, women 8.6%) among
adults aged 60 years and older.24 In the Australian
National Survey of Mental Health and Well-being 2007,
including the age group 65–74 years, the prevalence of
any antidepressant use amounts to 7.4%, and of anxioly-
tics, sedatives or hypnotics to 7.9% in the past 2 weeks.25
In a representative sample of community-dwelling adults
aged 60 years and older in Ireland, regular exposure to
CNS drugs include antidepressants (prevalence 7.4%),
hypnotics (5.5%), anxiolytics (2.7%) and opioid analge-
sics (3.1%).10 A direct comparison of these findings with
our results is impossible due to differences in the defin-
ition of psychotropic drugs (eg, phytomedicines are also
considered in our study) and observation windows as
well as study populations. Comparative studies, including
Germany and other European countries, however, dem-
onstrate that psychotropic drug use is generally lower
among adults in Germany than in Western European—
but higher than in Eastern European countries.26–30
Patterns of alcohol consumption differ widely between
countries and are influenced by drinking cultures and
social norms.31 32 Alcohol use is found to be consistently
high among older adults with a range between 40% and
60% and a higher use in men than in women in
Belgium,33 USA9 34 and Spain.35 Prevalence rates of
risky drinking in international studies are difficult to
compare because definitions of standard drinking size,
alcohol consumption guidelines32 and definitions of
Figure 1 Prevalence of psychotropic drug use and alcohol consumption among adults aged 60–79 years. German Health
Interview and Examination Survey for Adults (DEGS1) 2008–2011. A1, psychotropic drug use only, no alcohol use (n=387,
17.5%, 95% CI 15.5% to 19.6%). A2, combined use of psychotropic drugs and alcohol (but not risky drinking) (n=17, 0.7%, 95%
CI 0.4% to 1.2%). A3, daily alcohol use, but not risky drinking, no psychotropic drug use (n=99, 3.9%, 95% CI 2.9% to 5.1%).
A4, psychotropic drug use combined with risky drinking (but not daily) (n=22, 1.0%, 95% CI 0.6% to 1.7%). A5, psychotropic
drug use combined with daily risky drinking (n=59, 2.1%, 95% CI 1.5% to 2.9%). A6, daily risky alcohol drinking, but no
psychotropic drug use (n=293, 11.9%, 95% CI 10.3% to 13.7%). A7, risky drinking only, no daily alcohol use and no
psychotropic drug use (n=82, 2.6%, 95% CI 1.9% to 3.5%). One hundred and forty-two persons with missing values for
psychotropic drug use, risky drinking or daily alcohol drinking were excluded; 1407 non-users of psychotropic drugs who neither
drink daily nor riskily are not shown in the figure. All percentages were weighted according to the German national population of
31 December 2010; Daily alcohol drinking, drinking of alcohol-containing beverages at least once a day; Risky drinking, average
daily alcohol consumption of ≥20 g for men and ≥10 g for women.
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Table 4 Alcohol consumption among psychotropic drug users aged 60–79 years—overall and in major subgroups: German Health Interview and Examination Survey for
Adults (DEGS1) 2008–2011
Alcohol consumption according to frequency Alcohol consumption according to quantity
At least once a week At least once a day Moderate drinking* Risky drinking†
Psychotropic drugs N n % 95% CI n % 95% CI n % 95% CI N % 95% CI
Any psychotropic drugs 518 227 45.7 39.9 to 51.6 76 12.9 9.6 to 17.2 319 62.7 56.8 to 68.2 82 14.2 10.9 to 18.3
Antidepressants 173 68 41.4 31.2 to 52.4 21 10.4 6.1 to 17.3 93 51.4 41.4 to 61.4 24 14.7 8.9 to 23.3
Hypnotics and sedatives 98 47 50.1 37.5 to 62.6 15 17.0 8.8 to 30.3 57 62.4 49.8 to 73.5 19 18.7 11.3 to 29.5
Antidementia drugs 97 43 44.2 31.1 to 58.1 15 13.5 7.3 to 23.8 67 68.9 56.4 to 79.2 13 11.3 5.7 to 21.0
Narcotic analgesics 96 40 38.5 27.1 to 51.3 15 12.5 7.0 to 21.4 55 59.8 48.0 to 70.6 15 11.1 6.3 to 19.0
Benzodiazepines and related drugs 84 36 46.8 32.4 to 61.7 7 7.7 3.0 to 18.4 50 62.2 46.2 to 75.9 12 14.1 6.0 to 29.6
Antiepileptics 63 28 50.3 32.9 to 67.5 12 19.0 9.3 to 34.8 36 60.7 44.3 to 75.0 10 12.2 5.8 to 24.0
*Men >0 and<20 g, women >0 and<10 g/day.
†Men ≥20 g, women ≥10 g/day.
All percentages were weighted according to the German national population of 31 December 2010.
Table 5 Factors associated with psychotropic drug use and alcohol consumption among adults aged 60–79 years—overall and in subgroups of interest: German Health Interview and Examination Survey for Adults (DEGS1) 2008–2011











At least once a
week








0.213 0.106 0.190 0.120 0.216 0.209 0.186 0.117 0.059
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Sex
Women 1.83 1.27 to 2.64 2.66 1.54 to 4.59 3.00 1.79 to 5.04 4.40 2.01 to 9.63 1.85 1.00 to 3.43 0.28 0.22 to 0.36 0.21 0.15 to 0.29 0.46 0.35 to 0.61 0.61 0.27 to 1.37
Age group, years
70–79 1.19 0.85 to 1.65 1.75 1.17 to 2.60 0.90 0.54 to 1.5 1.32 0.78 to 2.23 0.75 0.4 to 1.39 1.07 0.84 to 1.36 1.10 0.82 to 1.48 0.90 0.66 to 1.23 1.20 0.62 to 2.34
Region of residence*
Central Germany 1.05 0.74 to 1.50 1.35 0.80 to 2.28 0.95 0.57 to 1.59 1.35 0.67 to 2.71 1.06 0.54 to 2.09 1.47 1.10 to 1.98 1.19 0.82 to 1.72 0.78 0.53 to 1.13 1.60 0.59 to 4.35
Southern Germany 1.09 0.72 to 1.64 1.14 0.66 to 1.98 1.33 0.75 to 2.36 1.31 0.61 to 2.83 1.09 0.49 to 2.45 2.35 1.72 to 3.22 1.95 1.34 to 2.86 1.45 0.96 to 2.21 1.46 0.51 to 4.19
Social status
Lower 1.22 0.77 to 1.94 0.38 0.19 to 0.76 0.88 0.44 to 1.74 0.59 0.24 to 1.43 2.49 1.07 to 5.80 0.44 0.30 to 0.66 0.95 0.60 to 1.52 0.53 0.34 to 0.81 1.24 0.43 to 3.61
Middle 1.08 0.76 to 1.55 0.72 0.45 to 1.15 1.01 0.58 to 1.75 0.68 0.33 to 1.39 1.29 0.58 to 2.84 0.73 0.52 to 1.03 1.00 0.73 to 1.37 0.65 0.46 to 0.92 1.26 0.54 to 2.96
Living alone
Yes 1.11 0.80 to 1.55 1.15 0.65 to 2.02 1.57 1.02 to 2.43 0.64 0.33 to 1.25 0.91 0.49 to 1.71 0.71 0.52 to 0.98 0.65 0.44 to 0.98 0.86 0.61 to 1.22 1.21 0.54 to 2.69
Smoking
Smoker 1.05 0.67 to 1.65 1.03 0.46 to 2.29 1.00 0.59 to 1.69 1.74 0.71 to 4.27 1.84 0.81 to 4.18 1.16 0.78 to 1.73 2.60 1.69 to 4.00 2.41 1.52 to 3.82 1.44 0.55 to 3.78
Ex-smoker 1.18 0.82 to 1.72 1.85 1.13 to 3.02 0.84 0.50 to 1.40 2.30 1.18 to 4.49 1.78 0.95 to 3.36 1.30 0.98 to 1.72 1.22 0.88 to 1.68 1.62 1.18 to 2.21 1.38 0.70 to 2.70
Health status
Worse 1.74 1.28 to 2.36 1.09 0.71 to 1.66 1.39 0.85 to 2.29 1.26 0.74 to 2.14 3.59 1.64 to 7.85 0.76 0.58 to 0.98 0.74 0.53 to 1.03 0.73 0.54 to 0.99 1.88 1.03 to 3.43
Certified disability
Yes 1.60 1.17 to 2.18 0.62 0.38 to 1.01 1.52 0.97 to 2.36 1.02 0.58 to 1.79 2.00 0.99 to 4.05 0.77 0.58 to 1.04 0.57 0.41 to 0.80 0.66 0.48 to 0.92 0.89 0.48 to 1.64
Polypharmacy†
Yes 4.30 3.11 to 5.94 2.82 1.69 to 4.70 5.39 3.03 to 9.57 4.08 2.20 to 7.59 5.94 2.34 to 15.0 0.91 0.71 to 1.16 1.31 0.96 to 1.80 1.03 0.78 to 1.36 2.46 1.10 to 5.48
ORs and 95% CI were derived from logistic regression models with all variables as independent variables and were weighted according to the German national population on 31 December
2010. Figures in bold denote statistical significance. References are: man, 60–69 years, Northern Germany, upper social status, not living alone, never smoker, worse health status, having no
certified disability and no polypharmacy.
*Regions: Northern Germany (federal states: Berlin, Brandenburg, Bremen, Hamburg, Lower Saxony, Mecklenburg-Vorpommern, Schleswig-Holstein); Central Germany (Hesse, North
Rhine-Westphalia, Saxony, Saxony-Anhalt, Thuringia), Southern Germany (Baden-Württemberg, Bavaria, Rhineland-Palatinate, Saarland).


















risky drinking19 vary widely between countries and
studies.32 For example, in the USA, drinking limits are
two standard drinks or 28 g of alcohol per day for men
and one standard drink or 14 g of alcohol for women,
while in Germany, the threshold for risky drinking is set
at ≥20–24 g/day for men and ≥10–12 g/day of alcohol
for women.20 21 32 In the USA, the National Health and
Nutrition Examination Survey 2005–2008 finds that
53.6% of people 65 years and older are non-drinkers
and 8.3% consume alcohol daily or almost daily in the
past 12 months.36 In this study, 14.5% of the older
alcohol consumers drink alcohol in excess of limits
recommended by the National Institute on Alcohol
Abuse and Alcoholism (NIAAA), namely drinking no
more than three drinks a day and no more than seven
drinks in a week.36 An analysis of the 2005 and 2006
National Survey on Drug Use and Health (NSDUH)
assessing past-month alcohol use finds that among
people aged 65 years and older, 13% of men and 8% of
women report at-risk alcohol use (defined as two or
more drinks on a usual drinking day within the past
30 days) and more than 14% of men and 3% of women
report binge drinking (defined as five or more drinks
on the same occasion on at least 1 day in the past
30 days).37 The NSDUH 2010 finds that 7.6% of people
aged 65 years and older practice binge- and 1.6% heavy
drinking (defined as five or more drinks on the same
occasion on each of 5 or more days in the past
30 days).38 In Australia, ∼18% of men and 4% of women
aged 65–74 years are heavy drinkers (>14 drinks/
week).39 In the UK, 27% of men and 14% of women
aged 65 years and older are excessive drinkers (drinking
on 5 or more days last week).40 Similar to our findings,
in a Belgian study, about one in five older adults
(20.5%) practices heavy drinking (>8 glasses/week).33 In
an Irish study 19.7%10 and in a Spanish study 7.8%35 of
older adults consume alcohol riskily. The former study
defined risky drinking according to NIAAA recommen-
dation,10 while the latter defined risky drinking as ≥40 g
alcohol per day for men and ≥24 g alcohol per day for
women,35 much higher than the thresholds used in our
study. The thresholds used in our study are lower than
those in some other studies, which may partly account
for the prevalence differences between studies.
The American Geriatrics Society suggests that benzo-
diazepines or other sedative-hypnotics should not be
used in older adults as first choice for insomnia,
agitation or delirium because of the substantial risks
associated with them.41 Concomitant use of alcohol and
psychotropic drugs, particularly sedatives, hypnotics and
benzodiazepines, may produce additional sedation
and increase greatly the risk of injuries caused by falling
and other accidents among older adults.5 Although
‘concurrent’ or ‘concomitant’ use of psychotropic drugs
and alcohol has been investigated in previous
studies,2 9 12 14 42 due to differences in observational
windows for drug use and alcohol exposure, it actually
cannot be guaranteed that participants were exposed to
the two substances at the same time in these
studies.2 9 12 14 42 In the present study, we investigate
daily alcohol drinking among psychotropic drug users to
increase the possibility of a simultaneous exposure of
the two substances at the same day. Among those who
used any psychotropic medicines, ∼13% drink daily with
no substantial differences between subgroups of psycho-
tropic drugs (table 4). As most of those daily drinkers
consume alcohol also riskily, this poses a great risk of
interactions. Consistent with our findings, 18.0% of
older adults taking antidepressants, 14.8% taking
opioids, 13.0% taking antiepileptics, antipsychotics or
hypnotics are found to be heavy drinkers in a large
population-based study in Ireland.10 In a national repre-
sentative sample of adults aged 60 years and older in
Spain, 36.5% of sleeping pill users are moderate and
5.6% heavy alcohol drinkers.35 In our study, 62.4% of
hypnotic and sedative users consume alcohol moderately
and 18.7% riskily. Again, definition of risky drinking
may explain some of the differences.
We identified certain groups with an increased risk of
exposure to psychotropic substance use. Those who
already belong to a vulnerable group (eg, worse health
status, disability, polypharmacy) or women are also more
frequently exposed to psychotropic drug use. European
studies confirm these findings.27 43 Male sex, people
with an upper SES, those living with a partner, smokers
and those with a better health status are more frequently
daily alcohol consumers. These factors are consistent
with studies on alcohol use in the USA,44 Belgian,33
Ireland10 and Finland.45 In particular, we find that
people with a worse health status and polypharmacy are
more likely to use a combination of the two substances.
Generally, we assume that polypharmacy defined by the
number of prescription drugs is related to health status
based on the fact that polypharmacy is closely associated
with multimorbidities (and thus probably poor health
status). Yet, polypharmacy defined by the number of any
drugs used may be related to the style of coping with
health issues. However, sensitivity analyses suggest there
is no substantial difference between the two different
definitions of polypharmacy in our study. Health profes-
sionals should pay attention when prescribing psycho-
tropic drugs to these vulnerable people.
Strengths of our study include the large sample size
and using nationally representative data and standar-
dised valid data collection tools. The weighted results
allow generalisation to the community-dwelling older
adults in Germany. Recall bias concerning medicine use
is minimised by reducing the observation period to the
last 7 days before the interview and by asking people to
bring the packages of medication to the examination
sites. However, there are some limitations to our study.
First, we cannot exclude selection bias, as persons who
are hospitalised or institutionalised were not included.
Older community-dwelling people with cognitive impair-
ment, depression or other mental or physical severe
illness are likely to be under-represented in the national
10 Du Y, et al. BMJ Open 2016;6:e012182. doi:10.1136/bmjopen-2016-012182
Open Access
survey due to the need to travel to survey sites.
Therefore, estimation of psychotropic drug use may be
underestimated. A further weakness of our study is the
age limit of 79 years. Older people usually consume
more psychotropic medication.46 47 Additionally, under-
reporting of alcohol use is likely because people tend to
answer questions concerning these substances according
to social desirability.48
CONCLUSION
In summary, the use of psychotropic drugs and alcohol
is common among older adults in Germany. Despite the
high risk of synergetic effects of psychotropic drugs and
alcohol, more than half of those who use any psycho-
tropic drugs consume alcohol moderately or at least
once a week, while about 13–14% consumes alcohol
daily or riskily. Health professionals should pay attention
to particularly vulnerable people, such as those exposed
to polypharmacy and people with a worse health status.
Further investigations are needed to monitor trends in
the use of specific subgroups of psychotropic medicines
and to evaluate health effects in association with alcohol
consumption patterns among older adults over time.
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